Collegium Pharmaceutical (NASDAQ:COLL) Upgraded to Strong-Buy at StockNews.com

StockNews.com upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a buy rating to a strong-buy rating in a report released on Tuesday.

Other equities research analysts have also issued research reports about the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. HC Wainwright upped their target price on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, September 5th. Piper Sandler restated a “neutral” rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Finally, Truist Financial raised their price target on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.60.

Collegium Pharmaceutical Stock Performance

COLL stock opened at $38.44 on Tuesday. The firm has a 50 day moving average of $37.65 and a two-hundred day moving average of $35.48. The company has a quick ratio of 1.04, a current ratio of 1.11 and a debt-to-equity ratio of 1.71. Collegium Pharmaceutical has a 12 month low of $20.95 and a 12 month high of $42.29. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of 16.02 and a beta of 0.94.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.40 by $0.22. The firm had revenue of $145.28 million during the quarter, compared to analysts’ expectations of $143.94 million. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The business’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.13 EPS. As a group, equities analysts anticipate that Collegium Pharmaceutical will post 5.79 EPS for the current fiscal year.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the sale, the executive vice president now owns 120,161 shares of the company’s stock, valued at approximately $4,602,166.30. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the sale, the executive vice president now owns 120,161 shares of the company’s stock, valued at approximately $4,602,166.30. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Thomas B. Smith sold 9,593 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $36.62, for a total value of $351,295.66. Following the completion of the transaction, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 3.98% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Exchange Traded Concepts LLC grew its holdings in shares of Collegium Pharmaceutical by 8.3% during the third quarter. Exchange Traded Concepts LLC now owns 71,693 shares of the specialty pharmaceutical company’s stock worth $2,770,000 after purchasing an additional 5,469 shares during the last quarter. Ritholtz Wealth Management lifted its stake in Collegium Pharmaceutical by 13.7% in the third quarter. Ritholtz Wealth Management now owns 44,189 shares of the specialty pharmaceutical company’s stock valued at $1,707,000 after buying an additional 5,333 shares during the period. CWM LLC lifted its holdings in shares of Collegium Pharmaceutical by 97.5% in the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock worth $58,000 after purchasing an additional 736 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Collegium Pharmaceutical by 124.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 792 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of Collegium Pharmaceutical by 8.7% in the 3rd quarter. SG Americas Securities LLC now owns 18,285 shares of the specialty pharmaceutical company’s stock worth $707,000 after purchasing an additional 1,470 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.